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diagnoais is still probiematic. Effective causal treatment is available 
only for infections with B. bugdoferi and HGE. By contrast, primary 
prevention by imniunization is at hand against arboviruses only. The 
efficacy of vaccines against B. burgdotjki recently studied in the USA 
has yet to be determined in Europe. 
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Postenteropathic hemolytic uremic syndrome (HUS) is preceded by 
diarrhca or hemorrhagic colitis and is characterized by inicro- 
angiopathic hemolytic anemia, throinbocytopenia and acute renal 
failure. It has been associated with entcrohemorrhagic Esrliericliia coli 
(EHEC) isolated from patients during large food- and water-borne 
outbreaks. The bacteria produce several well-characterized virulence 
factors such as: Shiga toxin (Stx) which is cytotoxic to human renal 
endothelial and epithelial cells and rabbit intestinal epithelial cells; 
intimin, an outer-membrane protein, which mediates intimate 
intestinal colonization, and its receptor, E. coli secretory protein EspE, 
which is transferred from the bacteria to the eukaryotic cell; Esps A, 
I3 and 11, which activate the signal transduction events necessary for 
the formation of intestinal attachment and effacement lesions; and 
lipopolysaccharide. Both lipopolysaccharide and Stx-2 are important 
for disease developiiieiit in a mouse inodel of EHEC infection. Mice 
develop gasti-ointestinai, neurologic and systemic symptoms, 
gloniernlar and tubular apoptosis, necrotic and apoptotic foci in the 
colon and fragmented erythrocytes. These aspects of disease resemble 
human HUS. Even mice inoculated with EHEC strains that do not 
produce intimin or Esp A and B develop similar symptoms and 
pathology. Children with HUS mount an antibody response to 
intimin, Esp A and Esp B which may be useful for detection of 
EHEC infection. Infected chiidren also secrete large amounts of  
interleukin-6 in their urine. Stimulation of pediatric renal tubular 
cells with Stx leads to the secretion of large amounts of interleukin- 
6, which may play a role in the host response to EHEC infection. 
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Antimicrobial spectrum of moxifloxacin 
A. Dalhoff. R o p r  AG, Plrarnza Research Center, Wnppertal, Gcrrriany 
Moxifloxacin is a new 8-methoxyquinolonc that is highly effective 
against all predominant respiratory pathogens, including: Gram- 
positive (i.e. Strcytococitrs pnrurnoniaej, Gram-negative (i.e. Haemo- 
pliiltrs iriiitenznc and ,bforaxellu catarrhah) and atypical (i.e. Clilanzydia 
pwetrvnoniac and Lc@oncl/a pneirmophi/a) bacteria. In contrast to 
fluoroquinolone agents, which showed greater Gram-negative than 
Gram-positive activity, moxifloxacin has been shown to be highly 
active against S .  pncuinoniae, including penicillin-resistant strains 
(MICWIF 0.06-0.12 nig/L) while retaining excellent Gram-negative 
activity (MlCsus for H. itzflueirzae and M .  catarrhah (including beta- 
lactamase-producing strains) <0.12 mg/L). Several studies of dis- 
sociated fluoroquinolone resistance have shown that moxifloxacin 
may have a lower potential than other quinolones to induce bacterial 
resistance. This phenomenon may be attributable to rnoxifloxacin's 
high intrinsic activity for two intracellular targets: DNA topo- 
isomerase IV (Grain-positivr organicins) a n d  DNA gr , ise  (Graiii- 
negative organisms). Addition of a methoxy group to Nl-cyclo- 
propyl flnoroquinolones improves lethal activity Conseqiiently, C% 
rnethoxy derivatives, such as moxifloxacin, restrict the acquisition of 
resistance by bacterial populations; moxifloxacin retains high activity 
against first- and second-step ciprofloxacin- aiid ofloxac in-resistant 
mutants. Hence, the employment of ii~oxifloxaciii for the manage- 
ment of respiratory tract infections may be ecologicnlly prcfcrable, 
since its high in vitro potency and reduced propensity to elicit 
bacterial resistance may curtail the spread of resistant strain\. This 
presentation will review the in vitro profile of inoxifloxxin vcr\us 
other fluoroquiiiolones and conventional firrt-line agent5 for thc 
management of conimunity-acquired respiratory tract infection\. 
p] Pharmacokinetics and pharmacodynamics 
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Pharmacokinetic aiid pharmacodyiiamic data for antibdctcrial agents 
can be integrated into several ratios, including: (1) the wed under the 
conceiitration-tiiiie curve (AUC) to the ininiinum inhibitory c011- 
centration of the pathogen (AUCIMIC) or AUIC (which is thc 
AUC/MIC normalized for 24 h), and (2) the peak \eruiii 
) to the MIC (C,,,.,,/MIC). With other quino- 
lones, AUIC values above 125 and C,,,,,/MIC ratios of 8-10 have 
been associated with optimal antibacterial activity. Lower values nny 
relate to less rapid bactericidal activity and the selection of resistant 
bacteria. This target AUIC may be achieved with a singlc antibiotic 
or it can be the sum ofAUIC values oftwo or iiiore antibiotics. There 
is considerable variability in the actual AUIC value for patients when 
antibiotics are given in their usually recommended dotages. The 
achievement of minimally effective antibiotic action, contisting of an 
AUIC above 125, is associated with bacterial eradication in about 7 
days for beta-lactams and quinolones. When AUIC is increased 
to 250, the quinolone ciprofloxacin (which disyhys i n  vivo 
concentration-dependent bacterial killing) can eliininatc thr bxterial 
pathogen in 1-2 days. Beta-lactams, even when d o d  to an AUIC 
of 250, often require longer treatment duration to eliminate the 
bacterial pathogen, because the in vivo bacterial killing rate is slower 
with beta-laccams than with the quinolones. This remain\ true evcn 
at AUIC values of 250 for both conipounds, which i\ theoretically 
identical dosing. The  new 8-mcthoxyqiiinolone agrnt nioxifloxxin 
has been shown to reach AUIC and C,,,.a,/MI(:wj values considerably 
greater than the ideal values of 125 and 12, respectively, thdt are 
necessary to effect rapid eradication of potential pathogens. The C,,,.,, 
long half-life (10-12 h) and inherent in vitro antibacterial activity 
against a broad range of pathogenic bacteria suggest that n~oxifloxacin 
will be useful for the treatment of a variety of respiratory tract and 
other infections. 
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Acute exacerbations of chronic obstryctive pulmonary disease 
(COPD) are common, as a reason for both general practice c o n u -  
tation7 and hospital admissions. They have a major impact on  
patients' quality of life, which may take up to 6 weeks to return to 
baseline. Bacterial infection of the respiratory inucosa occurs in at 
least half of the cases. This attracts dn inflaminatory responre which 
may clear the infection. Spontaneous resolution is less likely to occur 
4 0  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  5 S u p p l e m e n t  3 
in patients with impaired lung defenses, and established infection may 
lead to deterioration in already borderline lung function or in a co- 
morbid condition. Some patient? also harbor bacteria in their ainvays 
when in a stable condtion, and this stimulates chronic inflammation. 
We do not know whether chronic infection contributes to decline 
in lung function, or to the frequency of exacerbations. Significant 
benefit from antibiotics has been demonstrated in patients with 
moderate to severe exacerbations defined by increased dyspnea, 
sputum production and sputum purulence. The prevalence of resist- 
ance to commonly prescribed beta-lactam and macrolide antibiotics 
in the bacterial pathogens causing exacerbations has increased. 
Antibiotics should be targeted at  those patients with more severe 
exacerbations and risk factors contributing to poor outcome; treat- 
ment is usually empirical and new agents, such as moxifloxacin,. are 
more successful in terms of bacteriologic eradication. Future studies 
should compare new and standard agents in patients with more severe 
disease, and consider using new modes of evaluation. 
Sinusitis overview 
R. Siegert. Ear, Nose and Throat Department, University of Luebeck, 
Luebeck, Germany 
Introduction: Acute sinusitis is associated with significant morbidity 
and represents an important cause of primary care practitioner 
consultation. The primary cause of acute sinusitis is viral or bacterial 
infection. In recent years, there has been a significant increase in 
resistance rates in the major causative bacterial pathogens of acute 
sinusitis (i.e. Streptococcus pneumoniae, Haemophilus injuenzae and 
Moraxella catarrhalis); hence, it is important that new agents are 
available to provide broad and potent empirical coverage of all 
possible causative pathogens. Moxifloxacin is a novel 8-methoxy- 
quinolone with excellent in vitro activity against all potential respira- 
tory pathogens and a good pharmacokinetic/pharmacodynamic 
profile. Moxifloxacin has been shown to achieve rapid and high 
penetration (with levels several-fold in excess of the MICYOS of the 
causative pathogens of sinusitis for at least 36 h post-dosing) into the 
sinus tissues following oral, 400-mg doses. 
Methods: This presentation will review data from a recent meta- 
analysis comparing the results of four n~ultinational clinical trials in 
patients with acute sinusitis treated with either 400 mg of moxi- 
floxacin or a comparator (cefuroxime). 
Results: The meta-analysis revealed that the mean eradication rate 
for all isolates combined (96%) is in accordance with the high clinical 
efficacy of moxifloxacin (96%) resolution/iniprovement). The bac- 
teriologic etiology for cefuroxime-treated patients was comparable to 
that of the moxifloxacin-treated population, with slightly lower 
resolution/improvement (90%) and eradication (93%) rates for 
cefuroxime. The modal moxifloxacin MIC was 0.25 nig/L for S. 
pneumoniae, 0.064 mg/L for H .  iq'henzae and 0.125 mg/L for M .  
catarrhalis. 
Conclusions: Moxifloxacin was highly successful, in terms of 
both clinical efficacy and bacteriologic eradication rates, in the 
treatment of acute sinusitis. 
[?TiEl Safety profile of moxifloxacin 
R. Stahlniann. University Hospifal Benjamin Frankliw, Freie 
Uuiiwsitaer Berlin, Berlin, Germany 
Moxifloxacin IS a new 8-methoxyquinolone with excellent in vitro 
Gram-positive and Gram-negative activity and a promising 
pharmacokinetic/pharmacodynamic profile. This presentation will 
summarize the current knowledge surrounding fluoroquinolone 
toxicity and will review the results of a recent meta-analysis of the 
moxifloxacin clinical safety database comprising a total of 20 phase I1 
and Ill trials. 
Data from 4926 patients with exposure to moxifloxacin and 3415 
patients with exposure to comparators revealed that the incidences of 
adverse drug reactions (ADRs) were comparable among all treatment 
groups. The majority of ADRs were mild and transient, and no 
unexpected severe reactions occurred. The overall ADR discon- 
tinuation rate observed with moxifloxacin was 3.8%. The most 
frequently reported adverse events in patients treated with moxi- 
floxacin were nausea (7.2%) and diarrhea (5.7%) with low dis- 
continuation rates (0.8% and 0.5% respectively); dizziness was 
reported by 2.8% of patients (discontinuation rate 0.5%). Moxi- 
floxacin is a photostable fluoroquinolone and there was no drug- 
related case of phototoxicity. 
As is the case with all new drugs, at present no clear-cut statement 
can be made about rarely occurring adverse reactions (at incidences 
of <0.1%). However, analysis of this rather large clinical database 
indicates that the safety and tolerability profile of moxifloxacin com- 
pares favorably with other quinolones recognized to be well tolerated 
(e.g. ciprofloxacin). 
Molecular methods in the diagnostic 
laboratory: when to start and where to stop 
Bias associated with discrepant analysis 
A. Hadgu, Centersfor Disease Control, Division of STD Prevention, 
Atlanta, GA, lJS4 
The purpose of this presentation is to show that the sensitivity and 
specificity estimates obtained by 'discrepant analysis' are upwardly 
biased. Discrepant analysis is a widely used technique that attempts 
to provide estimates of sensitivity and specificity in the presence of 
an imperfect gold standard. Discrepant analysis has been used in the 
evaluation of Chlamydia tradtomalis, Neisseria gonorrhoeae, Clostridirrm 
d$cik, Mycobacteriron fubercuIosis, k@onella species, Toxopplasma gondii, 
Helicobacter pyluri, etc. This technique has been applied by many 
researchers to estimate the sensitivity and specificity of DNA-ampli- 
fication tests such as the plasmid-based ligase chain reaction (LCR) 
and polymerase chain reaction (PCR) tests. Moreover, earlier pack- 
age inserts of some of the DNA-amplification tests contain estimates 
of sensitivity and specificity based on 'discrepant analysis'. Even if one 
employs a periect test to resolve the discrepant results, discrepant 
analysis estimates of test sensitivity and specificity are still biased. 
Thus, this technique should not be adopted for evaluating the 
performance of a diagnostic test. 
Quality control of nucleic acid amplification 
methods 
G.T. Noordhoek. Public Healfh Laboratory, Medical Microbiology, 
Leeuwarden, Netherlands 
Diagnostic tests based on nucleic acid amplification (NAA) are now 
generally applied in clinical microbiology laboratories. The sensitivity 
and specificity of the NAA-based tests provide a powerful tool for 
rapid detection, identification and quantification of niicroorganisins. 
However, specially when low numbers of organisms have to be 
detected, false-negative and false-positive results may occur and the 
reliability of the methods is sometimes questionable. Quality control 
